September 2023 - Page 19 of 20

FridaySep 01, 2023 3:45 pm

QualityStocksNewsBreaks – Reflex Advanced Materials Corp. (CSE: RFLX) (OTCQB: RFLXF) (FWB: HF2) Looking to Improve North America’s Graphite Infrastructure Efficiencies to Meet Surging Demand

Reflex (CSE: RFLX) (OTCQB: RFLXF) (FWB: HF2) is advancing its flagship Ruby Graphite Project in Beaverhead County in southwestern Montana. “With its ‘mine-to-market’ strategy, Reflex aims to improve domestic specialty mineral infrastructure efficiencies to meet surging national demand from North American manufacturers, effectively positioning itself as one of the only North American suppliers of high purity natural graphite for hi-tech applications… Preliminary results from the TDEM and magnetic survey have demonstrated promising anomalies, indicating the presence of conductive structures, several new anomalies, and potential graphite mineral deposits within the Ruby Graphite property. The survey data will be integrated with existing…

FridaySep 01, 2023 2:43 pm

QualityStocksNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Positioned Favorably with Worldwide License to Anti-IL-17 NanoAbs

BiondVax (NASDAQ: BVXV), a biotechnology company that recently signed an exclusive worldwide license to develop and commercialize innovative alpaca-derived nanosized antibodies (“NanoAbs”) targeting IL-17 cytokines as treatments for psoriasis and psoriatic arthritis, recently received coverage in analysis by Aegis Capital Corp. The report, which reiterated a buy recommendation and $70 target price for BVXV, contained analysis highlighting a deal valued at approximately $2.4 billion for Eli Lilly and Company’s (NYSE: LLY) acquisition of DICE Therapeutics Inc. (NASDAQ: DICE), a biopharmaceutical company that develops oral therapeutic candidates – such as DC-806 and DC-853, both oral interleukin-17 (“IL-17”) inhibitors – currently in…

FridaySep 01, 2023 1:09 pm

QualityStocksNewsBreaks – Why Prospera Energy Inc. (TSX.V: PEI) (OTC: GXRFF) (FRA: OF6B) Is ‘One to Watch’

Prospera (TSX.V: PEI) (OTC: GXRFF) (FRA: OF6B), a public oil and gas exploration, exploitation, and development company focusing on conventional oil and gas reservoirs in Western Canada, uses its experience to develop, acquire and drill assets with potential for primary and secondary recovery. “Prospera’s core properties include more than 42,000 cumulative acres across Cuthbert, Luseland and Heart Hills in Saskatchewan and Red Earth and Pouce Coupe in Alberta. In total, the company estimates that there are half a billion barrels of oil in place at these sites accounting for 20+ years of forward project lifespan, with as little as 8%…

FridaySep 01, 2023 12:55 pm

QualityStocksNewsBreaks – GolfLync Inc.’s Pebble Beach Sweepstakes Provides Once-in-a-Lifetime Opportunity for Golf Enthusiasts

GolfLync, the company behind the GolfLync app – a social network for matching golf games and players, previously announced the launch of the GolfLync Pebble Beach Sweepstakes. “This exciting sweepstakes gives golf enthusiasts a chance to win a dream golf trip to the iconic Pebble Beach Resorts, renowned as the No. 1 Golf Resort in America… As the greatest public golf course in America, as rated by Golf Digest, Pebble Beach has a rich history of hosting prestigious tournaments, including the U.S. Open and, for the first time in 2023, the U.S. Women’s Open. This sweepstakes provides a once-in-a-lifetime opportunity…

FridaySep 01, 2023 12:09 pm

QualityStocksNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures Patent Protection in ‘Some of the Most Important Markets in the World’

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, recently received a patent from the China National Intellectual Property Administration. “The granted patent broadly covers the use of the company’s drug candidate REQORSA(R) immunogene therapy in combination with PD-1 antibodies, such as Keytruda(R), to treat cancers. The REQORSA gene therapy in combination with Keytruda is the subject of the company’s ongoing Acclaim-2 clinical trial for the treatment of non-small cell lung cancer (‘NSCLC’). In this trial, the company is enrolling and treating patients with advanced, metastatic NSCLC whose disease progressed…

FridaySep 01, 2023 11:50 am

QualityStocksNewsBreaks – Knightscope, Inc. (NASDAQ: KSCP) K5 and K1 ASRs to Patrol New York-Based Pharmaceutical Facility

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots (“ASRs”) and blue light emergency communication systems, has announced a new 7-robot contract with a publicly traded biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. The new client subscribed to one K5 ASR assigned to patrol a 4-story garage and six K1-Tower ASRs to monitor building entrances, open areas and parking lots throughout the corporate campus. The announcement reads, “A secure and resilient pharmaceutical supply chain in the United States is the best means to ensure that U.S. patients and the health care system…

FridaySep 01, 2023 11:24 am

QualityStocksNewsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) CEO Responds to Question Asked on ‘Making Money with Charles Payne’

Mullen Automotive’s (NASDAQ: MULN) CEO and Chairman David Michery appeared on “Making Money with Charles Payne” on Fox Business on Thursday, Aug. 31, to discuss the lawsuit against large brokerage firms for unlawful trading practices of the company’s stock and other matters. The company today announced its response to a question asked during Michery’s appearance on the program, which aired on Fox Business at 2:55 p.m. ET on Aug. 31, 2023. Michery and Wes Christian of the law firm of Christian Attar were interviewed by host Charles Payne to discuss various matters and, notably, Mullen’s recent lawsuit against large brokerage…

FridaySep 01, 2023 10:48 am

QualityStocksNewsBreaks — Cepton Inc. (NASDAQ: CPTN) CEO Explains Lidar, Eye Safety During Proactive Investors Interview

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance lidar solutions, is in the spotlight. Cepton CEO and cofounder Dr. Jun Pei was a guest during a recent Proactive Investors interview. During the interview, Pei and Proactive Investors host Steve Darling discussed the importance of lidar technology and eye safety. Pei specifically talked about lidar impact on human eyes and eye safety, explaining Cepton’s commitment to safety and its approach to ensuring safety standards are met. He noted regulations require that any devices placed on vehicles adhere to eye safety standards and also explained that many people have misconceptions…

FridaySep 01, 2023 10:30 am

SuperCom Ltd. (NASDAQ: SPCB) Helping Governments Improve Public Safety, Reduce Recidivism Rates through Suite of Proven Products Focused on Effectiveness of Home Confinement with Electronic Monitoring

SuperCom provides offender monitoring products and solutions under the best-of-breed PureSecurity Electronic Monitoring (“EM”) Suite The PureSecurity EM Suite includes the PureOne ankle bracelet, PureTag ankle bracelet, PureCom base station, PureTrack smartphone, PureProtect mobile phone application, PureBeacon radiofrequency (“RF”) device, and the PureMonitor cloud-based software A growing body of research supports home confinement with EM as an effective and appropriate alternative to imprisonment for lower-risk offenders Research shows that people assigned to home confinement with EM have similar or better outcomes than those who serve time in prison, as measured by future criminality By providing EM solutions, SuperCom is helping…

FridaySep 01, 2023 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyes What Is Considered One Of America’s Most Serious Health Problems

The ADA reports that 37.3 million Americans had diabetes in 2019, and the number has been growing by an average 1.4 million each year 95% of Americans with diabetes are diagnosed with type 2 diabetes, which can lead to heart disease, stroke, kidney damage, and nerve damage when left untreated Lexaria’s DIAB-A22-1 pre-clinical diabetes study using DehydraTECH(TM)-CBD in obese diabetic-conditioned animals shows promising results, prompting the company to investigate for human trial Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced its intent to conduct a human clinical trial to examine its patented DehydraTECH(TM)-processed cannabidiol (“CBD”)…

Site Search

Company Search

Month: September 2023